Background: Ankylosing spondylitis is a member of the group of the spondyloarthropathies with a
strong genetic predisposition. Complete fusion results in a complete rigidity of the spine, a condition
known as "bamboo spine". There is no cure for AS, although treatments and medications can reduce
symptoms and pain. Objective: To evaluate bone specific alkaline phosphatase in Iraqi patients with
Ankylosing Spondylitis, and evaluate the efficacy and safety of long term infliximab therapy.
Material and methods: Eighty five AS patients are enrolled in this study with a mean age of 36 ± 41
years & age range from 16-56 years, mean duration equal to 12.08. Results: a significant decrease
of mean serum level of ALP in group 3 patients who treated with infliximab ( 142.14 ± 4.68 ng/ml ,
p < 0.05 level ) compared with mean serum level of ALP in G1(167.10 ± 10.37 ng/ml ) , and a non
significant decrease of mean serum level of ALP in G2 (154.08 ± 6.40 ng/ml , p = 0.205 ) compared
with mean serum level of ALP in G1 (167.10 ± 10.37 ng/ml). Conclusion: An elevate serum level of
bone specific alkaline phosphatase in Iraqi patients with ankylosing spondylitis , the attribution of
this elevation is increasing bone production due to increase the activity of the disease lead to
increase the ability of osteoblast to produce BALP . This cross - sectional study reveals the efficacy of
infliximab and the good safety treatment in patients with activeankylosing spondylitis.
(FULL ARTICLE LINK) Read more ...
25/10/2014
|
|
|
